Fig. 2From: HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal womenDisease outcome of AI-treated ER-positive breast cancer patients. OS and DFS are displayed for all patients (top row), premenopausal (< 46 years; middle row), and postmenopausal (≥ 46 years, bottom row) breast cancer patients treated with AI. The p values were calculated using the log-rank test (Mantel–Cox) and are indicated in each graphBack to article page